Oral contraception in Denmark 1998-2010

被引:19
作者
Wilson, Nadia M. [1 ]
Laursen, Maja [2 ]
Lidegaard, Ojvind [1 ]
机构
[1] Univ Copenhagen, Rigshosp, Univ Hosp, Gynecol Clin, DK-2100 Copenhagen, Denmark
[2] Danish Med Agcy, Copenhagen, Denmark
关键词
Combined oral contraceptives; estrogen dose; oral contraceptives; progestins; progestogens;
D O I
10.1111/j.1600-0412.2012.01416.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background. Oral contraceptives (OC) are the most popular contraception in Denmark. Overall figures on use are well described, but more detailed use patterns according to type and age need to be updated. Objectives. To assess trends in the use of OC including progestogen-only pills among Danish women in 19982010 and to describe in detail use patterns in 2010. Design. Annual cross-sectional prescription statistics. Setting. Denmark. Population. Danish women 1049 years old. Material and methods. Analysis of prescription data from the National Registry of Medicinal Products Statistics from 1 January 1998 through 31 December 2010. Results. Combined OC (COC) with 50 mu g estrogen decreased their market share from 3% in 1998 to zero in 2010, and COC with 3040 mu g estrogen decreased to 50% in 2010, in contrast, COC with 20 mu g estrogen increased to 46% in 2010. Progestogen-only pills accounted for 4%. COC with levonorgestrel decreased, while the use of pills with desogestrel and gestodene among two-thirds of current users was constant. Conclusion. Low-dose COCs gradually replaced middle-dose pills. Pills with newer progestogens are used primarily by young women, and 85% of users in 2010 were on products with desogestrel, gestodene, drospirenone or cyproteroneacetate. We still need low-dose pills with 1st and 2nd generation progestogens on the Scandinavian market.
引用
收藏
页码:810 / 815
页数:6
相关论文
共 50 条
[31]   Nomegestrol acetate-17b-estradiol for oral contraception [J].
Burke, Anne .
PATIENT PREFERENCE AND ADHERENCE, 2013, 7 :607-619
[32]   ALTERED GROWTH-HORMONE SECRETION DURING ORAL CONTRACEPTION [J].
KARLSSON, R ;
EDEN, S ;
VONSCHOULTZ, B .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1990, 30 (04) :234-238
[33]   Venous thrombembolism, thrombophilic defects, combined oral contraception and anticoagulation [J].
Johannes Ott ;
Regina Promberger ;
Ulrike Kaufmann ;
Johannes C. Huber ;
Peter Frigo .
Archives of Gynecology and Obstetrics, 2009, 280
[34]   ORAL CONTRACEPTION AND BENIGN BREAST DISEASES - POINT-OF-VIEW OF THE EPIDEMIOLOGIST [J].
LE, MG ;
CHARREAU, I .
BULLETIN DU CANCER, 1991, 78 (04) :357-363
[35]   The evolution of combined oral contraception: improving the risk-to-benefit ratio [J].
Burkman, Ronald ;
Bell, Carrie ;
Serfaty, David .
CONTRACEPTION, 2011, 84 (01) :19-34
[36]   ORAL CONTRACEPTION AFFECTS OSTEOCALCIN SERUM PROFILES IN YOUNG-WOMEN [J].
KARLSSON, R ;
EDEN, S ;
VONSCHOULTZ, B .
OSTEOPOROSIS INTERNATIONAL, 1992, 2 (03) :118-121
[37]   The role of triphasic levonorgestrel in oral contraception: A review of metabolic and hemostatic effects [J].
LachnitFixson, U .
GYNECOLOGICAL ENDOCRINOLOGY, 1996, 10 (03) :207-218
[38]   Educational technology on oral contraception: construction shared with nurses reproductive assistance [J].
Ataide Rodrigues, Ivaneide Leal ;
Souza Teixeira, Lorena Francielly ;
Vidal Nogueira, Laura Maria .
REVISTA DE PESQUISA-CUIDADO E FUNDAMENTAL ONLINE, 2019, 11 (01) :53-58
[39]   Oral contraception following abortion A systematic review and meta-analysis [J].
Che, Yan ;
Liu, Xiaoting ;
Zhang, Bin ;
Cheng, Linan .
MEDICINE, 2016, 95 (27)
[40]   Reduced serum cholecystokinin and increase in body fat during oral contraception [J].
Hirschberg, AL ;
Bystrom, B ;
Carlstrom, K ;
vonSchoultz, B .
CONTRACEPTION, 1996, 53 (02) :109-113